NEW YORK, NY / ACCESSWIRE / July 18, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
CareDx, Inc. (NASDAQ:CDNA)
CONTACT JAKUBOWITZ ABOUT CDNA:
https://claimyourloss.com/securities/caredx-inc-loss-submission-form/?id=29944&from=1
This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.
Lead Plaintiff Deadline : July 22, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company's RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company's testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Spero Therapeutics, Inc. (NASDAQ:SPRO)
CONTACT JAKUBOWITZ ABOUT SPRO:
https://claimyourloss.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29944&from=1
Class Period : October 28, 2021 - May 2, 2022
Lead Plaintiff Deadline : July 25, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Unity Software Inc. (NYSE:U)
CONTACT JAKUBOWITZ ABOUT U:
https://claimyourloss.com/securities/unity-software-inc-loss-submission-form/?id=29944&from=1
Class Period : March 5, 2021 - May 10, 2022
Lead Plaintiff Deadline : September 6, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies in Unity's product platform reduced the accuracy of the Company's machine learning technology; (ii) the foregoing was likely to have a material negative impact on the Company's revenues; (iii) accordingly, Unity had overstated the Company's commercial and/or financial prospects for 2022; (iv) as a result, the Company was likely to have to reduce its fiscal 2022 guidance; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/708936/LAWSUITS-FILED-AGAINST-CDNA-SPRO-and-U--Jakubowitz-Law-Pursues-Shareholders-Claims